好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Myelopathy in the setting of fentanyl abuse
General Neurology
P3 - Poster Session 3 (5:30 PM-6:30 PM)
4-039
To present an unusual case of myelopathy related to fentanyl use.
The opioid crisis has reached unprecedented levels in recent years.  Heroin, an inexpensive and widely available illicit opioid, has been associated with a myriad of neurologic complications.  Acute transverse myelitis in the setting of heroin use after a period of abstinence has been well described.  It is postulated to be related to an immunologic response, direct toxin effect, and/or vasculopathy.  Fentanyl has never previously been reported with myelopathy.
Case report from a tertiary medical center.
A 26-year-old man with a history of opiate abuse presented with quadriparesis and numbness.  He reported an 8 day period of abstinence to heroin prior to the day of presentation.  However, he continued his daily use of a quarter of a 100 mcg fentanyl patch.  The day of presentation, he instead used one half of a 100 mcg fentanyl patch sublingually and fell asleep on a couch.  When he awoke 3 hours later, he was barely able to move any of his limbs.

 

Examination demonstrated flaccid quadriparesis and a sensory level at C3.  MRI showed a T2 hyperintense intramedullary lesion at C4-7 and signal abnormality in adjacent paraspinal muscles.  He received pulse steroids for treatment.  On the second day of hospitalization, patient developed respiratory weakness and required intubation.  His condition gradually improved subsequently.  At time of discharge to rehab, he was regaining strength but was not yet ambulatory. 
Myelopathy in the setting of fentanyl use after a period of abstinence likely represents a similar entity to the well described heroin myelopathy.  Fentanyl myelopathy has not been previously reported.
Authors/Disclosures
Olivia Tong, MD
PRESENTER
Dr. Tong has received personal compensation for serving as an employee of Alexion Pharmaceuticals.
Alina Masters-Israilov, MD (Weill Cornell Medical College, Department of Neurology) Dr. Masters-Israilov has received publishing royalties from a publication relating to health care.
Lenore C. Ocava, MD (NYC Health+Hospital/Jacobi/Albert Einstein COM/) No disclosure on file
Jillian Rosengard, MD (Montefiore Medical Center) Dr. Rosengard has nothing to disclose.
Peter C. Mabie, MD (Albert Einstein College of Medicine, Neurology) Dr. Mabie has nothing to disclose.